Abstract: The present invention is directed to a novel method of determining inhibitors of proteolytically active coagulation factors, referred to herein as anticoagulants, in a sample, in particular the qualitative detection of direct thrombin and factor Xa inhibitors in a sample. The method of the present invention allows a qualitative determination of the nature anticoagulants present in a sample. This can be achieved with only one coagulation-based test. The method can be used in a test kit, including a point-of-care (POC) system.

Abstract: The compounds of formula (I) wherein X represents a bond or NH—CH(C?O)—(CH2)3+n—NH—R5, n represents 0, 1 or 2, R1, R4 and R5—independently from each other—represent hydrogen, possibly substituted C1-C6-alkyl, amidino or tetra-C1-C6-alkylamidinium, R2 represents hydrogen or possibly substituted C1-C6-alkyl or R1 and R2 together with the residue to which they are bound represent a 5- to 7-membered, saturated ring, R3 represents C1-C12-alkoxy, C1-C12-alkylamino, possibly substituted aryl-C1-C6-alkylamino, possibly substituted heteroaryl-C1-C6-alkylamino, possibly substituted aryl-C1-C6-alkoxy or possibly substituted heteroaryl-C1-C6-alkoxy, and R6 represents hydrogen or, when n is 1, also amino or together with R1 and the residue to which R6 and R1 are bound a 5- to 7-membered, saturated ring, as well as their physiologically acceptable salts are new.

Abstract: A hematological assay is described in which the blood coagulation potential of a body fluid is assessed by reacting a sample of the body fluid with an amount of an activator reagent comprising: (a) a predetermined amount of factor Xa or a hematologically equivalent mutant thereof, and (b) a predetermined amount of factor Va, a hematologically equivalent mutant thereof or an enzyme activating endogenous factor V, (c) (optionally) phospholipids. The reagent may be dry (e.g. lyophilised) or in an aqueous solution preferably buffered to a pH from 6 to 10 (preferably 7 to 8), if desired incubating, if necessary inducing coagulation by the addition of one or more coagulation accelerants such as calcium chloride, and establishing a value indicative of the coagulation potential, e.g. by measuring the time to clotting on an optical coagulometer or through use of a chromogenic substrate. It is preferred to use at (b) factor V activator from purified Russell's Viper venom (RVV-V).

Abstract: The present invention relates to the use of conjugated linoleic acid (CLA) for the topical treatment of fatty deposits and cellulite and to new topical compositions and to cosmetic and dermatological topical compositions for the treatment of fatty deposits and cellulite comprising CLA as well as kits comprising CLA for said treatment.

Abstract: Closure cap (1) for closing a liquid container (4) such as a vial, flask etc., having takeout means (14) for withdrawing liquid from the container without removing the cap and thereafter re-closing it, and protecting means (22) for proving the authenticity of the content of the container characterized by a skirt portion (2) and a cover (3), a recessed trough (6) in the cover, a fodable spout (14) having a spherical bearing portion (15) seated in a cylindrical portion (7) of the trough, and a channel (17) extending lengthwise through the spout.

Abstract: The invention relates to the compounds of general formula (I), that are present with respect to R1 as racemates as well as L- or D-configured compounds and as E/Z mixtures as well as E or Z isomers and in which the various symbols are defined as in the description and the claims, as well as to the salts thereof, for use as therapeutic agents and for diagnostic purposes. The inventive compounds can be processed to medicaments or to diagnostic agents that are used for the diagnosis, therapy and prevention of urokinase- or urokinase-receptor associated diseases, for example for the treatment of tumors. The compounds are highly efficient in inhibiting growth and/or spread of malign tumors, for example tumor spread of pancreatic cancer, tumor growth of breast cancer and the formation of tumor metastases. The compounds of formula (I) and the salts thereof can be produced by conventional methods.

Abstract: The invention relates to oligopeptide derivatives whose C-terminal amino acid is arginine which is linked to the remainder of an electroactive aniline or aminoquinoline derivative by an amide bond. The oligopeptide derivatives are split by enzymes of the class of peptide hydrolases, especially proteinases and their inhibitors, of the coagulation system, the fibrinolytic system and the complement system. These oligopeptide derivatives serve as substrates for quantitatively determining such enzymes, especially thrombin, in complex sample liquids, especially capillary blood. This determination is carried out by measuring the increase in the water-soluble amperogenic aniline or aminoquinoline compound. The oligopeptide derivatives and their salts can be produced according to usual methods in peptide chemistry.

Abstract: A new expression vector for the production of a polypeptide in yeast. The vector includes a sequence coding for the polypeptide and other sequences allowing expression of the polypeptide only in yeast. The other sequences lack any non-yeast sequences. Other embodiments include a yeast strain comprising such a vector, a method for the production of the vector, a method for the production of the yeast strain by transformation of a yeast strain with the new vector, and a method for the production of a polypeptide in the transformed yeast strain by fermentation thereof followed by isolation of the polypeptide.

Abstract: The invention relates to an active ingredient combination containing erythrulose and a further reducing sugar with self-tanning properties, for example, dihydroxyacetone, which combination is used for artificially tanning the skin. Compared with compounds containing, for example, only dihydroxyacetone, said active ingredient combination and cosmetic compounds based thereon result in an even and longer-lasting colouring of the skin and prevent skin dehydration and uneven flaking.

Abstract: The method relates to a method for detecting disorders in the protein C system, and in particular for determining the activated blood coagulation factor V with increased stability with respect to decomposition by activated protein C.

Abstract: For temporary connection of two containers (1, 3) such as vials, bottles, etc. . . . , with guaranteed tightness thanks to a cylindrical screwing closing and connection plastic sleeve (4) having a plastic perforable membrane (7) located between its upper portion (6) and lower portion (5) including an elastomer sealing ring (13) fixed around a cylindrical plastic skirt (12) located in the inner lower portion (5), and an elastomer sealing plug (18) fixed by the collar (17) and the annular rib (16) in the inner upper portion (6), a cylindrical plastic skirt (12) coming in contact with the inner neck (10) of the glass or plastic vial (1), the whole assuring complete tightness of the system when stored and when used for the reconstitution of the product (2) contained in a glass or plastic vial (1) with a corresponding solvent (23) contained in a plastic solvent bottle (3).

Abstract: It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyuranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic and immunochromogenic tests have been developed.

Abstract: It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyaranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic aria immunochromogenic tests have been developped.

Abstract: The present invention relates to D,L-, L- and D-phenylalanine piperazides of formula (I) defined in claim 1 that inhibit blood coagulation, and thrombin and/or trypsin, respectively. The compounds are extraordinarily absorbable after oral, intraduodenal and in particular rectal administration and show only a low toxicity.

Abstract: D,L-, L- and D-phenyl alanine derivatives of formula (I) defined in claim 1 in which R.sub.1 is an amidino-, guanidino-, oxamidino-, aminomethyl- or amino group have been discovered which effectively prevent blood coagulation or thrombosis. The antithrombotically active compounds have low toxicity and may be administered by mouth, subcutaneously or intravenously.

Abstract: A method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes belonging to the Elapidae family, the activator comprising an increased plasma clotting activity in the presence of phospholipids and calcium ions; a reduced activity in the presence of Lupus Anticoagulant; an ability to facilitate clotting in a normal clotting time in the presence of platelet poor plasma, the plasma having normal or decreased levels of factor V, VII, VIII, IX, or X; and a major band with a molecular weight of 40,000 to 60,000 daltons on an SDS gel.

Abstract: The protein fraction from Leguminosae seeds, which is characterized by at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, by relative molecular masses from 3,000 to 30,000 g/mole, by a content of total nitrogen of 14 to 20% and amino nitrogen of 1 to 2% related to the protein content and by further parameters defined in claim 1, is appropriate for the care of skin and for the treatment of inflammatory skin diseases, whereby the protein fraction is generally used as a concentrate of active substances or e.g. as a cream, lotion, emulsion, gel, face mask, powder or plaster.

Abstract: Meizothrombin- and thrombin-inhibiting inhibitors which do not bind bivalent cations and which are used for the anticoagulant pretreatment of blood samples to be used in the determination of the functions and/or changes of state of blood cells and blood corpuscles, and for treating devices and receptacles used for taking and/or receiving blood samples.

Abstract: A method and composition for assaying protein C is described. The method comprises reacting a protein C-containing medium with a protein C-activating activator preparation obtained from venom of the snake Agkistrodon contortrix, or venom of another snake species which undergoes an immunological cross-reaction with the venom of Agkistrodon contortrix, to cause maximum activation of protein C and subsequently determining the quantity of activated protein C, said quantity being proportional to the amount of protein C in said medium. Also disclosed is a method and composition for treating thrombotic disorders with the activator preparation and a method of obtaining the activator preparation by culturing of a cloned microorganism.

Abstract: This invention discloses use of superoxide dismutase (SOD) as an agent for the protection of the skin against inflammatory reactions associated with chemical irritation and acne. Topical application of SOD in a formulation attenuates dermal injury associated with the induction of reactive oxygen species by a wide variety of chemical irritants, associated with inflammation, and associated with acne.